• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Weekly Roundup: June 21-25

ICYMI, some of this week’s featured content includes the newest regulatory updates for cemiplimab for BCC and upadacitinib for PsA. Plus, stories on practice management, webinar recaps, and more.

POLL: What is your go-to treatment for vitiligo?

Study: WaterWipes Reduces Facial Pressure from PPE

A study found WaterWipes, a baby wipe comprised of 99.9% water and a drop of fruit extract, helped reduce facial pressure injuries (FPI) caused by prolonged wear of personal protective equipment (PPE).

C-Jun Protein Linked to Psoriasis

The pro-inflammatory transcription factor is critical for the expression of IL-23, which is known to play a role in psoriasis.

NPF COVID-19 Task Force Issues Updated Guidance Statements

The National Psoriasis Foundation has updated its guidance statements for individuals living with psoriatic disease during the COVID-19 pandemic.

Transitioning Your Practice Post-COVID-19

In the first part of our 3-part recap series of our Roadmap to Recovery webinar, panelists discussed how the dermatology practice changed during COVID-19 and what changes they plan on keeping.

First Genetic Test for Hair Loss

New TrichoTest aims to help clinicians diagnose and treat alopecia.

ABM Vivace Receives 2MHz FDA Clearance

Vivace microneedling device receives FDA clearance on 2MHz radiofrequency setting.

FDA Approves New Dose for Dupilumab Pre-filled Pen

The FDA has approved a single-dose pre-filled pen for dupilumab (Dupixent, Sanofi and Regeneron) for at-home administration.

Guselkumab Demonstrates Efficacy in Phase 3b Study

COSMOS phase 3b study data demonstrated the effectiveness of guselkumab in patients diagnosed with psoriatic arthritis.

New Way to Detect Skin Cancer

DermTech offers a new way to detect skin cancer without patients having to go under the knife.

How to Make Your Practice Stand Out

Suneel Chilukuri, MD, FAAD, FACMAS, takes Dermatology Times® inside his practice, Refresh Dermatology located in Houston, Texas, to demonstrate how they separate themselves from competitors.

I Operated on the Wrong Nevus

In this month's Legal Eagle column, David J. Goldberg, MD, JD, dives into wrong-site surgeries and malpractice lawsuits.

The Mystery of the Skin Care Product Allergy

In this month's Cosmetic Conundrums column, Dermatology Times® Chief Medical Editor Zoe Diana Draelos, MD, discusses allergies from skin care products and how to prevent adverse reactions.

Review Your Finances Now to Keep on Track in 2021

It’s always a good time to do a financial revIew. You’ll make sure your savings and investments are aligned with your goals and reduce income taxes.

The Benefits of Adding Aesthetic Procedures Into Your Practice

In the second part of our 3-part recap series of our Roadmap to Recovery webinar, panelists discuss what aesthetic procedures dermatology practices can add to their existing list to increase profit and patient satisfaction.

FDA Fails to Provide Approval Decision on Upadacitinib for PsA

The FDA announces it did not meet the June 25 PDUFA action date on the sNDA for active psoriatic arthritis treatment, upadacitinib.

Cemiplimab Approved for BCC in Europe

The European Commission has approved cemiplimab for the treatment of locally advanced or metastatic basal cell carcinoma in adults.

The Mainstream Patient: June 24, 2021

This week’s edition of The Mainstream Patient features stories about face mapping, benzene contamination in sunscreen, natural retinol, ceramides in skin care, plus more.

Related Videos
3 experts are featured in this series.
© 2024 MJH Life Sciences

All rights reserved.